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PCV8
ESTIMATING POPULATION BLOOD PRESSURE
CONTROL AMONG US HYPERTENSIVE
PATIENTS
Yuan Y1, Chen R1, L’Italien G1, Karaniewsky R2
1Bristol-Myers Squibb, Princeton, NJ, USA; 2Bristol-Myers
Squibb, Plainsboro, NJ, USA
OBJECTIVES: Treatment-to-Goal analyses are com-
monly used to predict population blood pressure (BP)
control rates for antihypertensive agents based on mean
BP lowering. However, control rates are frequently inac-
curate because variability in BP reduction and baseline
BPs are not considered. This study presents a new
methodology that improves on population BP control
estimates. METHODS: Untreated hypertensive patients
(n = 2483) from the Third National Health and Nutri-
tion Examination Survey formed the test-sample. Monte
Carlo simulation trials (MCST) of 500 patient-level BP
reductions were generated from 3 underlying distribu-
tions: normal, lognormal, and beta. BP control, deﬁned
as SBP < 140 and DBP < 90mmHg, was estimated by 3
methods: parametric- MCST-based means and variances
were used to generate BP lowering data, assuming a
normal distribution, and were subtracted from test-
sample baseline BPs; point-estimate- mean BP reductions
from MCST were directly subtracted from baseline BPs;
bootstrapping- MCST BP reductions were bootstrapped
with replacement and applied to the test-sample. Para-
metric and point-estimate results were compared to more
comprehensive bootstrapping estimates for each simula-
tion trial. We also investigated the relative performance
of each method in the subgroup patients at three hyper-
tension stages deﬁned in the JNC VI guideline. RESULTS:
We assumed a mean (+-SD) BP lowering of 20(12) and
14(7) mmHg systolic and diastolic. Parametric, boot-
strapping, and point-estimate methods projected BP
control rates of 66.9, 67.3, and 75.5%, respectively. The
Point-estimate method frequently projected inaccurate
control rates while the parametric results were shown
consistent with the bootstrap method under a wide range
of model conditions. CONCLUSIONS: Regardless of 
the underlying data distribution, parametric method pro-
vides more accurate control rates than point-estimate.
Since patient-level BP reduction trial data are frequently
unavailable to researchers, this parametric method can 
be used to generate more accurate treatment to goal
analyses. This methodology can be extended to other
therapeutic areas to estimate treatment effectiveness.
PCV9
META-ANALYSIS OF STATINS IN THE
LOWERING OF LOW-DENSITY LIPOPROTEIN
CHOLESTEROL TO EUROPEAN
ATHEROSCLEROSIS SOCIETY TARGET USING
ROSUVASTATIN AS A COMMON COMPARATOR
Morrell J1, Edwards S2
1Fitznells Manor Surgery, Ewell, Surrey, United Kingdom;
2AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
OBJECTIVE: To combine the results of the four pub-
lished clinical trials comparing rosuvastatin with either
atorvastatin, pravastatin or simvastatin by meta-analysis
to quantify the magnitude of difference in the percentage
of patients failing to achieve the European Atherosclero-
sis Society (EAS) target for LDL-C of <3mmol/L at 12
weeks. Patients included in the clinical trials had an initial
LDL-C ≥160 (4.1mmol/L) and <250mg/dL (6.5mmol/L).
METHODS: Meta-analysis of patients failing to achieve
the EAS target at 12 weeks calculated by intention-to-
treat (ITT) analysis. ITT was deﬁned as, “patients being
analysed in the treatment arm that they entered at 
randomisation, regardless of whether they dropped-out,
received the incorrect treatment or withdrew before com-
pletion of the trial”. RESULTS: Rosuvastatin 10mg is
more effective at lowering LDL-C to the EAS target than
atorvastatin 10mg, pravastatin 20mg and simvastatin 20
mg at 12 weeks. There is an increase in the relative risk
of failing to achieve the EAS target for LDL-C with ator-
vastatin 10mg (RR 2.31; 95%CI: 1.76 to 3.04), pra-
vastatin 20mg (RR 3.91; 95%CI: 3.05 to 5.03) and
simvastatin 20mg (RR 2.41; 95%CI: 1.83 to 3.16), com-
pared to rosuvastatin 10mg. A chi-squared test was
carried out to investigate possible heterogeneity in each
of the comparisons. Signiﬁcant heterogeneity was not
detected in any of the comparisons made. CONCLU-
SIONS: Compared to rosuvastatin 10mg, there is a sig-
niﬁcant increase in the risk of failing to achieve the EAS
target for LDL-C with atorvastatin 10mg, pravastatin 
20mg and simvastatin 20mg at 12 weeks.
PCV10
DEFINING OUTCOMES IN STUDIES OF
BLEEDING MORBIDITY ASSOCIATED WITH
ANTICOAGULATION THERAPY
Ofori BD1, Davey PG1, Goudie B2,Timoney A3
1University of Dundee, Dundee, United Kingdom; 2Westgate
Health Centre, Dundee, United Kingdom; 3Tayside Health
Board, Dundee, United Kingdom
OBJECTIVES: The reported incidence of bleeding asso-
ciated with oral anticoagulation therapy varies widely.
The study objectives were to identify good quality evi-
dence about risk of bleeding and to investigate the impact
of study heterogeneity on outcomes. METHODS: A
search was made of MEDLINE and EMBASE for ran-
domised controlled trials and inception cohort studies
between January 1990 and March 2002. Selection crite-
ria were: anticoagulation monitored by INR, percent-
age time within range stated, and criteria for deﬁning a
major bleed stated. The sensitivity of diagnostic criteria
for bleeding events was investigated by assembling a six-
month cross sectional retrospective cohort of anticoagu-
lated patients. Outcome events in this cohort were then
assessed against the criteria for “major bleeds” proposed
by each reviewed study. RESULTS: Twelve studies were
identiﬁed that met the selection criteria. Signiﬁcant vari-
ation was seen in the major bleed rates across the studies
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(P < 0.0002, chi-square; range from 0.5 to 6.6 events per
100 patient years) conﬁrming signiﬁcant heterogeneity in
the results. In the assembled cohort of 3998 patients there
were 174 admissions in 6 months, of which 117 included
some evidence of warfarin related bleeding. Applying the
criteria from the 12 different studies resulted in a range
of 24 to 117 of these events being classiﬁed as “major
bleeds”. The 3 studies with most restrictive deﬁnitions
reported from 0.5 to 1.1 events per 100 patient years,
compared with from 1.5 to 2.8 events per 100 patient
years for the 4 studies with least restrictive deﬁnitions.
CONCLUSIONS: It is essential for future outcomes
research in anticoagulant therapy that consistent deﬁni-
tions of major adverse outcomes are applied. The in-
consistent deﬁnitions used in the 12 published studies
reviewed make it impossible to assess the impact of other
differences between studies, for example in INR range or
% of time within range.
PCV11
EFFECTIVENESS OF CLINICAL PATHWAYS FOR
PATIENTS WITH HEART FAILURE
Panella M, Marchisio S
University of Eastern Piedmont “A. Avogadro”, Novara, Italy
OBJECTIVES: To evaluate the effectiveness of the care
provided to patients with heart failure through the im-
plementation of clinical pathways at the hospital “The
Holy Family” in Novafeltria (Italy). METHODS: We per-
formed a pre-post analysis model to evaluate the effect of
the application of clinical pathways on process indicators,
outcome indicators and on the costs sustained to treat the
patients. We compared the results obtained treating the
patients according to the clinical pathway with the results
obtained before implementing the pathway. We studied
quantitative variables with t Student test or Wilcoxon
test, qualitative variables with X2 test. RESULTS: Two
hundred forty-six cases were included in our study. These
subjects were all the patients admitted for hearth failure
to the hospital and treated by the staff. We compared the
age, the sex and the disease staging (NYHA scores at
admission) of the patients of the 2 groups and we did not
ﬁnd any signiﬁcant difference. After the implementation
of the pathway we observed a signiﬁcant improvement of
the core processes. We observed a reduction of the rate
unscheduled readmissions within 31 days from discharge
(from 6.74% to 2.94%; p > 0.05), of the average length
of stay (from 10.89 days to 7.86; p < 0.05) and of inpa-
tients’ mortality (from 17.42% to 4.41%; p < 0.01). The
average costs for patient increased from 2.399 US$ 
to 2.596 US$ (p > 0.05). CONCLUSION: Our primary
ﬁnding was that the implementation of the clinical
pathway for heart failure improved patients’ outcomes
and the quality of the core processes. Our results also
showed that this was possible without incrementing the
costs. This study has important limitations too. The initial
measurement occurred a year before the full implemen-
tation of the pathways. Thus, it is possible that some of
the observed improvement represented a natural drift
toward higher performance.
PCV12
ACHIEVEMENT OF THE EUROPEAN
ATHEROSCLEROSIS SOCIETY LDL-C TARGET
BY HYPERCHOLESTEROLAEMIC PATIENTS
RECEIVING ROSUVASTATIN COMPARED 
TO ATORVASTATIN, PRAVASTATIN OR
SIMVASTATIN: AN EVIDENCE-BASED 
MEDICINE APPROACH
Morrell J1, Edwards S2
1Fitznells Manor Surgery, Ewell, Surrey, United Kingdom;
2AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
OBJECTIVE: To determine the number needed to treat
(NNT) for one additional patient to achieve the European
Atherosclerosis Society (EAS) target for LDL-C of <3
mmol/L at 12 weeks for rosuvastatin compared to ator-
vastatin, pravastatin or simvastatin. Patients included in
the clinical trials comparing rosuvastatin with ator-
vastatin, pravastatin and simvastatin had an initial 
LDL-C ≥160 (4.1mmol/L) and <250mg/dL (6.5mmol/L).
METHODS: The rosuvastatin trials were speciﬁcally
designed to allow pooling of the data to provide summary
estimates of efﬁcacy. This design strategy minimised the
potential bias caused when pooling results by variation in
the event rates, differences in the outcomes considered,
effects of secular trends on disease risk, and differences
in clinical setting. The pooled efﬁcacy data was used as
the basis for the calculation of the NNTs. RESULTS:
Rosuvastatin 10mg is more effective at lowering LDL-C
to the EAS target than atorvastatin 10mg, pravastatin 20
mg and simvastatin 20mg at 12 weeks and this translates
into relatively small NNTs. By convention, NNTs are
rounded up to the nearest whole number of patients.
Rosuvastatin 10mg has an NNT of 4 compared to ator-
vastatin 10mg, 2 compared to pravastatin 20mg, and 4
compared to simvastatin 20mg (p < 0.001, all compar-
isons). CONCLUSIONS: As a general rule, an NNT of 6
or less might be considered “good” for an acute treat-
ment, while an NNT as large as 40 might be considered
“good” for a chronic treatment (depending on the dura-
tion of treatment and the severity of outcome). In this
context, an NNT of 4 for rosuvastatin 10mg compared
to the next best in class (atorvastatin 10mg) would be
considered a very favourable result.
PCV13
ENOXAPARIN USE IN PATIENTS WITH
MECHANICAL HEART VALVES REQUIRING
BRIDGING THERAPY FOR SUBTHERAPEUTIC
CHRONIC ORAL ANTICOAGULATION
Cross LB1, Hamann GL2, Campbell JD2, Dorko CS2,
Bailey LE2
1University of Tennessee Health Science Center, Memphis,TN,
USA; 2Regional Medical Center, Memphis,TN, USA
OBJECTIVES: Enoxaparin has been used for thrombo-
prophylaxis (TBX) when patients with mechanical heart
valves require bridging therapy for sub-therapeutic
chronic oral anticoagulation (COA). Due to recent
